Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Sweet and sour: the role of glycosylation for the anti-inflammatory activity of immunoglobulin G.

Böhm S, Kao D, Nimmerjahn F.

Curr Top Microbiol Immunol. 2014;382:393-417. doi: 10.1007/978-3-319-07911-0_18. Review.

PMID:
25116110
2.

The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Böhm S, Schwab I, Lux A, Nimmerjahn F.

Semin Immunopathol. 2012 May;34(3):443-53. doi: 10.1007/s00281-012-0308-x. Epub 2012 Mar 22. Review.

PMID:
22437760
3.

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo.

Anthony RM, Nimmerjahn F.

Curr Opin Organ Transplant. 2011 Feb;16(1):7-14. doi: 10.1097/MOT.0b013e328342538f. Review.

PMID:
21150612
4.

Evidence that calf bronchopneumonia may be accompanied by increased sialylation of circulating immune complexes' IgG.

Fratrić N, Gvozdić D, Vuković D, Savić O, Buač M, Ilić V.

Vet Immunol Immunopathol. 2012 Dec 15;150(3-4):161-8. doi: 10.1016/j.vetimm.2012.09.009. Epub 2012 Sep 23.

PMID:
23068275
5.

The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.

Collin M, Ehlers M.

Exp Dermatol. 2013 Aug;22(8):511-4. doi: 10.1111/exd.12171. Epub 2013 Jun 28. Review.

PMID:
23808883
6.

Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice.

Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P.

Clin Exp Immunol. 1996 Nov;106(2):259-64.

7.

Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.

Issekutz AC, Rowter D, Miescher S, Käsermann F.

Clin Immunol. 2015 Oct;160(2):123-32. doi: 10.1016/j.clim.2015.05.003. Epub 2015 May 14.

PMID:
25982320
8.

IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis.

Selman MH, Niks EH, Titulaer MJ, Verschuuren JJ, Wuhrer M, Deelder AM.

J Proteome Res. 2011 Jan 7;10(1):143-52. doi: 10.1021/pr1004373. Epub 2010 Jul 30.

PMID:
20672848
9.

Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G.

Einarsdottir HK, Selman MH, Kapur R, Scherjon S, Koeleman CA, Deelder AM, van der Schoot CE, Vidarsson G, Wuhrer M.

Glycoconj J. 2013 Feb;30(2):147-57. doi: 10.1007/s10719-012-9381-6. Epub 2012 May 10.

10.

7th International Immunoglobulin Conference: Mechanisms of action.

Basta M, Branch DR.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:111. doi: 10.1111/cei.12532.

11.
12.

Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.

Mimura Y, Kelly RM, Unwin L, Albrecht S, Jefferis R, Goodall M, Mizukami Y, Mimura-Kimura Y, Matsumoto T, Ueoka H, Rudd PM.

J Immunol Methods. 2016 Jan;428:30-6. doi: 10.1016/j.jim.2015.11.009. Epub 2015 Nov 26.

PMID:
26627984
13.

Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes.

Bondt A, Rombouts Y, Selman MH, Hensbergen PJ, Reiding KR, Hazes JM, Dolhain RJ, Wuhrer M.

Mol Cell Proteomics. 2014 Nov;13(11):3029-39. doi: 10.1074/mcp.M114.039537. Epub 2014 Jul 8.

14.

Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.

Nimmerjahn F, Anthony RM, Ravetch JV.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8433-7. Epub 2007 May 7.

15.

Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs.

Oefner CM, Winkler A, Hess C, Lorenz AK, Holecska V, Huxdorf M, Schommartz T, Petzold D, Bitterling J, Schoen AL, Stoehr AD, Vu Van D, Darcan-Nikolaisen Y, Blanchard V, Schmudde I, Laumonnier Y, Ströver HA, Hegazy AN, Eiglmeier S, Schoen CT, Mertes MM, Loddenkemper C, Löhning M, König P, Petersen A, Luger EO, Collin M, Köhl J, Hutloff A, Hamelmann E, Berger M, Wardemann H, Ehlers M.

J Allergy Clin Immunol. 2012 Jun;129(6):1647-55.e13. doi: 10.1016/j.jaci.2012.02.037. Epub 2012 Apr 12.

PMID:
22502800
16.

The other side of immunoglobulin G: suppressor of inflammation.

Aschermann S, Lux A, Baerenwaldt A, Biburger M, Nimmerjahn F.

Clin Exp Immunol. 2010 May;160(2):161-7. doi: 10.1111/j.1365-2249.2009.04081.x. Epub 2009 Dec 16. Review.

17.

The pro and anti-inflammatory activities of immunoglobulin G.

Lux A, Aschermann S, Biburger M, Nimmerjahn F.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i92-96. doi: 10.1136/ard.2009.117101. Review.

PMID:
19995755
18.

IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.

Fokkink WJ, Selman MH, Dortland JR, Durmuş B, Kuitwaard K, Huizinga R, van Rijs W, Tio-Gillen AP, van Doorn PA, Deelder AM, Wuhrer M, Jacobs BC.

J Proteome Res. 2014 Mar 7;13(3):1722-30. doi: 10.1021/pr401213z. Epub 2014 Feb 17.

PMID:
24533874
19.

Changes in the galactose content of IgG during humoral immune responses.

Lastra GC, Thompson SJ, Lemonidis AS, Elson CJ.

Autoimmunity. 1998;28(1):25-30.

PMID:
9754811
20.

Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface.

Selman MH, Derks RJ, Bondt A, Palmblad M, Schoenmaker B, Koeleman CA, van de Geijn FE, Dolhain RJ, Deelder AM, Wuhrer M.

J Proteomics. 2012 Feb 2;75(4):1318-29. doi: 10.1016/j.jprot.2011.11.003. Epub 2011 Nov 15.

PMID:
22120122

Supplemental Content

Support Center